Glycosylation profiling of triple-negative breast cancer: clinical and immune correlations and identification of LMAN1L as a biomarker and therapeutic target
Our GRS risk model demonstrates robust predictive capability for TNBC prognosis and immunotherapy response. This model offers a promising strategy for personalized treatment and improved clinical outcomes in TNBC.
Authors
- Qianru Yu (ORCID: https://orcid.org/0000-0003-3181-7235)
- Qian Zhao (ORCID: https://orcid.org/0000-0001-8103-8251)
- Songchang Shi (ORCID: https://orcid.org/0000-0001-5793-569X)
- Haoran Zhao (ORCID: https://orcid.org/0000-0002-2515-8897)
- Jiao Wang (ORCID: https://orcid.org/0000-0001-9875-5425)
- Xinhao Zhu (ORCID: https://orcid.org/0000-0002-5553-163X)
- Ci-Xiang Zhou
- Chang Liu (ORCID: https://orcid.org/0000-0003-2685-6651)
- Z. Li
- Xin Zhang (ORCID: https://orcid.org/0000-0003-0047-3134)
- Hanyi Zhong
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1521930
- Citations
- 1
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Shanghai Jiao Tong University
- Ruijin Hospital
- School of Medicine, Shanghai Jiao Tong University